Last reviewed · How we verify

Ultiva

Seoul National University Hospital · FDA-approved active Small molecule ✓ Verified May 2026 Quality 6/100

Ultiva is a Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved. Also known as: brand-named drug of remifentanil, Ultiva™, Remifentanil.

Remifentanil, marketed under the brand name Ultiva, is a potent, short-acting synthetic opioid analgesic drug used to relieve pain during surgery and as an adjunct to an anesthetic. Ultiva is also used for sedation and in combination with other medications for general anesthesia.

At a glance

Generic nameUltiva
Also known asbrand-named drug of remifentanil, Ultiva™, Remifentanil
SponsorSeoul National University Hospital
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Boxed warnings

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ultiva

What is Ultiva?

Ultiva is a Small molecule drug developed by Seoul National University Hospital.

Who makes Ultiva?

Ultiva is developed and marketed by Seoul National University Hospital (see full Seoul National University Hospital pipeline at /company/seoul-national-university-hospital).

Is Ultiva also known as anything else?

Ultiva is also known as brand-named drug of remifentanil, Ultiva™, Remifentanil.

What development phase is Ultiva in?

Ultiva is FDA-approved (marketed).

What are the side effects of Ultiva?

Common side effects of Ultiva include Nausea, Vomiting, Hypotension, Muscle rigidity, Bradycardia, Shivering. Serious adverse events: Respiratory depression, Bradycardia, Hypotension, Muscle rigidity.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing